2022 Hospital Imaging Nuclear Medicine 
AuntMinnie
APRIL 15, 2024
Total nuclear medicine patient study volumes decreased by 5.7% decrease in hospital-based studies and a 2.5% decrease in total procedures each year, with hospital-based procedures declining by 5.5% and non-hospital procedures increasing by 1.2%. and non-hospital procedures increasing by 1.2%. Of these, 5.8
Imaging Technology
JUNE 27, 2023
Urbain, MD, PhD, FASNC , professor of radiology/nuclear medicine and medicine, vice chair of theranostics, and director of nuclear medicine at Roswell Park Cancer Center at the University of Buffalo , Buffalo, New York. and ‘How can we ensure diversity in all parts of the nuclear medicine family?’
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JULY 1, 2024
Almost a third of imaging exam interpretations are performed by nonradiologists, according to a Harvey L. of all imaging studies for Medicare fee-for-service beneficiaries in 2022, but that the remaining 27.9% The team conducted a study that included data from 123 million 2022 Medicare Part B imaging claims.
AuntMinnie
MARCH 7, 2024
In 2023 compared with 2022, the total volume of positron emission tomography (PET) scans increased 10.2% from 1,401 estimated PET scans per system in 2022 to 1,495 in 2023. Want to share your knowledge of medical imaging? Want to share your knowledge of medical imaging? physicians reading PET scans per site.
Imaging Technology
JULY 3, 2024
of all imaging studies for Medicare fee-for-service beneficiaries in 2022, with the remaining 27.9% According to a written study summary released by HPI, market share varied by imaging modality; radiologists interpreted 97.3% of nuclear medicine (NM), and 33.9% of nuclear medicine (NM), and 33.9%
AuntMinnie
SEPTEMBER 20, 2024
Their findings were published September 19 in the Journal of Nuclear Medicine. Food and Drug Administration approved Pluvicto for patients with PSMA-positive metastatic castration-resistant prostate cancer in March 2022. Yet current data on its efficacy and toxicity profile are scarce. Median PSA PFS was 4.1 months
AuntMinnie
OCTOBER 31, 2023
Fibroblast activation protein inhibitor (FAPI)-PET/CT appears superior to standard FDG-PET/CT for detecting gastrointestinal cancer, with higher radiotracer uptake seen in most tumors, according to a study published October 26 in the Journal of Nuclear Medicine. Image courtesy of the Journal of Nuclear Medicine.
Expert insights. Personalized for you.
111 
Let's personalize your content